| STOCK FALLS |
| The News You Need Before You Need It |
Filed under: Market matters , Options , Financial Crisis First of all, let’s look at what hedging really is. Take, for example, a farmer who grows corn. He knows that his cost for growing corn is, say, $3.00 per bushel
Read the original post:
Should Geithner eliminate speculation in financial derivatives?
Filed under: AT and T (T) , Research in Motion (RIMM) Tel-Aviv based Ceragon Networks (NASDAQ: CRNT ) will be releasing its second quarter earnings on July 20. After a miserable first quarter, in which profits fell 95% over the year-ago quarter, investors are skittish about the stock’s prospects. My view: for investors, Ceragon is a good long-term play.
Go here to see the original:
Wireless Stock Watch: Shares of Ceragon are set for a rebound
Filed under: Stocks to Buy When my son had a huge boil under his arm, it turned out that it was filled with the killer staph, MRSA. It also turns out that my (otherwise) great doctor used a traditional lab to process the test, which took a week to determine it was MRSA. Cepheid (NASDAQ: CPHD ) manufactures the equipment and test that takes just two hours to do the same thing — and is better and cheaper than traditional tests
Continued here:
Biotech stock #3: Cepheid (CPHD)
Filed under: Stocks to Buy Imagine a company with 90%-plus margins and huge cashflow that uses its cash to carefully expand its business and buy back stock — with a P/E under 8! That’s Questcor Pharmaceuticals (NASDAQ: QCOR ). QCOR has a treatment that is approved for spasms from multiple sclerosis, but is mostly used to treat radical infantile spasms that kill or retard babies.
Filed under: Scandals , Business of sports It’s hard to know where to begin in addressing this interview, so you pretty much just have to watch it: Days after filing for Chapter 11 bankruptcy protection, retired outfielder Lenny Dykstra sat down with CNBC’s Jane Wells to explain what happened. The result is probably the most awkward 18 minutes and 32 seconds of television you’ll ever see in your life. It’s hard not to feel bad for him — it’s been an MC Hammer-like rise and fall, and I can’t even imagine what that’s like to go through.
Here is the original:
Lenny Dykstra’s trainwreck CNBC interview
Filed under: General Electric (GE) , Coca-Cola (KO) , International Business Machines (IBM) , Comfort Zone Investing Summertime….and the livin’ ain’t easy.
Excerpt from:
Comfort Zone Investing: The glass isn’t half empty — it’s half full
Filed under: Gilead Sciences (GILD) , Stocks to Buy Few would argue with the claim that Gilead Sciences (NASDAQ: GILD ) is the best-managed biopharma company on the planet.
The rest is here:
Biotech stock #1: Gilead Sciences (GILD)
Filed under: Gilead Sciences (GILD) , Stocks to Buy Last year, as the market sank, one group actually went up — large-cap, cashflow positive biotech and genomics companies.
Original post:
Six bang-for-your-buck biotech stocks
